Covid19
Conditions
Brief summary
The aim for this study is further to elucidate the presence of dysautonomia in post-covid-19 patients, by evaluating heart rate variability.
Detailed description
The COVID-19 pandemic is currently a serious global public health concern. This disease is caused by a novel coronavirus which was first discovered in Wuhan, China in 2019 and later spread rapidly throughout the world. Symptoms of the disease can manifest as fever, cough, encephalitis, myalgia, fatigue, muscle weakness, arthralgia, anosmia, and impairment in other bodily functions in the acute phase. In 17% to 67% of cases, COVID-19 patients will develop acute respiratory distress syndrome (ARDS) and critical illness. Besides the impact on the respiratory system, coronaviruses have an effect on other systems including the central nervous system, cardiovascular system, musculoskeletal system, and gastrointestinal system. Potential long-term secondary effects on the musculoskeletal system such as muscle weakness, decreased muscle mass, and myopathies have been brought under attention. Persisting symptoms in patients recovered from COVID-19 infection are frequently a complaint with at least 1 symptom, particularly fatigue and dyspnea. In recent papers, the authors commented on the potential role of dysautonomia in the post-covid-19 entity related to microangiopathy and endothelial injury. Such lesions were already reported in brain biopsy samples of severe COVID-19. Therefore, the aim of this study is further to elucidate the presence of dysautonomia in post-covid-19 patients, by evaluating heart rate variability.
Interventions
OTHERDysautonomia
Indicators of dysautonomia
Sponsors
Moens Maarten
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients with a diagnosed covid-19 infection that took place 2-8 weeks before study inclusion. * Cognitive and language functioning enabling coherent communication between the researcher and the participant. * French-or Dutch speaking persons.
Exclusion criteria
* Covid-19 infection \> 8 weeks ago. * The presence of one or more coexisting conditions known to affect HRV analysis (including but not limited to atrial fibrillation, numerous atrial or ventricular extra beats, paced rhythm, left ventricular bundle branch block, cancer, kidney or hepatic failure, and diabetes mellitus)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Heart rate variability | The change between baseline, 3 months (primary time endpoint), 6 months and 12 months | Heart rate variability will be measured using a 2-lead ECG. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Electrodermal activity | The change between baseline, 3 months (primary time endpoint), 6 months and 12 months | Electrodermal activity will be measured by applying two skin conductance sensors. |
| Respiration rate | The change between baseline, 3 months (primary time endpoint), 6 months and 12 months | Respiration will be measured using a respiration sensor (an elastic belt) . |
| Blood volume pulse | The change between baseline, 3 months (primary time endpoint), 6 months and 12 months | The blood volume pulse sensor uses fingertip photo plethysmography. |
| Functionality and disability | The change between baseline, 3 months (primary time endpoint), 6 months and 12 months | Functional status will be evaluated by the Post-COVID-19 Functional Status Scale. |
Countries
Belgium
Contacts
Primary ContactMarc Schiltz, MD
Outcome results
None listed